You are here: Industry Insights > chemotherapy

News List

New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients with Poor Response to Anti-Estrogen Therapy Who May b3cnewswire
April 25, 2019
New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients with Poor Response to Anti-Estrogen Therapy Who May Benefit from Neoadjuvant Chemotherapy.
Aluminium could aid delivery of chemotherapy drugs europeanpharmaceuticalreview
April 18, 2019
Aluminium could be key for the effective and efficient adsorption of chemotherapy drugs for targeted delivery and reduced side effects…
Researchers find new mechanism to control spread of breast cancer pharmaceutical-technology
January 23, 2019
Researchers at the Fred Hutchinson Cancer Research Center in Seattle, the US, have discovered how cells that have broken away from breast cancer tumours evaded chemotherapy and ....
FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) worldpharmanews
January 22, 2019
Roche announced that the US Food and Drug Administration has accepted the company's supplemental Biologics License Application for Tecentriq
UC Berkeley develops drug sponge to soak up chemotherapy side effects pharmaceutical-technology
January 11, 2019
Chemical engineers at the University of California, Berkeley (UC Berkeley) have developed a drug sponge that could absorb the residual chemotherapy drug and minimise cancer treatment side effects.....
UroGen’s urothelial cancer drug hits target, could prevent surgery pharmaphorum
January 10, 2019
Former Novartis oncology chief Liz Barrett’s decision to jump ship to lead the biotech UroGen appears to have been vindicated after the company announced top-line results showing its lead drug could change standard of care in a form of urothelial cancer.
Sprycel combo gets FDA approval pharmatimes
January 04, 2019
The US Food and Drug Administration has approved a new treatment for children one year of age and older, facing a type of blood cancer known as Philadelphia chromosome-positive (Ph+) acute lymphoblastic
ASH18: Bluebird’s anti-BCMA has a ‘clear lead’ in a crowded field fiercebiotech
January 02, 2019
This year’s ASH saw a plethora of presentations on BCMA-targeting drugs, but analysts at Jefferies say Bluebird Bio’s CAR-T therapy bb2121 “is still leading the pack.”....
FDA Approves Elzonris for BPDCN americanpharmaceuticalreview
December 27, 2018
The U.S. Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.....
Apixaban Prevents VTE in Cancer Patients Initiating Chemotherapy drugs
December 17, 2018
Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban versus placebo.....

Previous page 1 2 3 4 5 Next page